Inovio Pharmaceuticals, Inc. (LON:0A43)
London
· Delayed Price · Currency is GBP · Price in USD 1.739
0.00 (0.00%)
At close: Apr 17, 2025
Inovio Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 0.22 | 0.83 | 10.26 | 1.77 | 7.41 | Upgrade
|
| Revenue | 0.22 | 0.83 | 10.26 | 1.77 | 7.41 | Upgrade
|
| Revenue Growth (YoY) | -73.83% | -91.89% | 478.24% | -76.05% | 80.24% | Upgrade
|
| Cost of Revenue | 75.62 | 84.69 | 187.65 | 249.24 | 94.25 | Upgrade
|
| Gross Profit | -75.4 | -83.86 | -177.39 | -247.47 | -86.83 | Upgrade
|
| Selling, General & Admin | 37 | 42.88 | 76.19 | 53.75 | 37.25 | Upgrade
|
| Operating Expenses | 37 | 42.88 | 76.19 | 53.75 | 37.25 | Upgrade
|
| Operating Income | -112.4 | -126.74 | -253.57 | -301.22 | -124.08 | Upgrade
|
| Interest Expense | -0.18 | -1.22 | -1.25 | -1.94 | -8.7 | Upgrade
|
| Interest & Investment Income | 4.77 | 8.13 | 4.78 | 3.36 | 3.31 | Upgrade
|
| Earnings From Equity Investments | -1.17 | 0.77 | -4.06 | -0.99 | 31.97 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.55 | 0.09 | 0.17 | 0.35 | -75.79 | Upgrade
|
| EBT Excluding Unusual Items | -107.43 | -118.96 | -253.94 | -300.43 | -173.29 | Upgrade
|
| Impairment of Goodwill | - | -10.51 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.17 | 1.04 | -11.88 | -3.23 | 1.11 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 4.12 | Upgrade
|
| Asset Writedown | - | -1.98 | - | - | - | Upgrade
|
| Legal Settlements | - | -4.7 | -14 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.58 | Upgrade
|
| Pretax Income | -107.25 | -135.12 | -279.82 | -303.66 | -167.47 | Upgrade
|
| Earnings From Continuing Operations | -107.25 | -135.12 | -279.82 | -303.66 | -167.47 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 1.06 | Upgrade
|
| Net Income | -107.25 | -135.12 | -279.82 | -303.66 | -166.41 | Upgrade
|
| Net Income to Common | -107.25 | -135.12 | -279.82 | -303.66 | -166.41 | Upgrade
|
| Shares Outstanding (Basic) | 27 | 22 | 20 | 17 | 13 | Upgrade
|
| Shares Outstanding (Diluted) | 27 | 22 | 20 | 17 | 13 | Upgrade
|
| Shares Change (YoY) | 22.49% | 11.51% | 14.27% | 34.62% | 57.14% | Upgrade
|
| EPS (Basic) | -3.95 | -6.09 | -14.07 | -17.45 | -12.87 | Upgrade
|
| EPS (Diluted) | -3.95 | -6.09 | -14.07 | -17.45 | -12.87 | Upgrade
|
| Free Cash Flow | -104.56 | -124.69 | -217.18 | -216.94 | -179.5 | Upgrade
|
| Free Cash Flow Per Share | -3.85 | -5.62 | -10.92 | -12.47 | -13.88 | Upgrade
|
| Operating Margin | -51616.91% | -15233.26% | -2470.93% | -16972.34% | -1674.25% | Upgrade
|
| Profit Margin | -49254.27% | -16239.87% | -2726.67% | -17109.87% | -2245.39% | Upgrade
|
| Free Cash Flow Margin | -48019.06% | -14986.17% | -2116.34% | -12223.61% | -2422.00% | Upgrade
|
| EBITDA | -110.65 | -123.98 | -249.42 | -297.66 | -120.5 | Upgrade
|
| D&A For EBITDA | 1.75 | 2.77 | 4.15 | 3.56 | 3.59 | Upgrade
|
| EBIT | -112.4 | -126.74 | -253.57 | -301.22 | -124.08 | Upgrade
|
Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.